Literature DB >> 24323901

Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Yasmine Touil1, Wassila Igoudjil, Matthieu Corvaisier, Anne-Frédérique Dessein, Jérôme Vandomme, Didier Monté, Laurence Stechly, Nicolas Skrypek, Carole Langlois, Georges Grard, Guillaume Millet, Emmanuelle Leteurtre, Patrick Dumont, Stéphanie Truant, François-René Pruvot, Mohamed Hebbar, Fan Fan, Lee M Ellis, Pierre Formstecher, Isabelle Van Seuningen, Christian Gespach, Renata Polakowska, Guillemette Huet.   

Abstract

PURPOSE: Metastasis and drug resistance are the major limitations in the survival and management of patients with cancer. This study aimed to identify the mechanisms underlying HT29 colon cancer cell chemoresistance acquired after sequential exposure to 5-fluorouracil (5FU), a classical anticancer drug for treatment of epithelial solid tumors. We examined its clinical relevance in a cohort of patients with colon cancer with liver metastases after 5FU-based neoadjuvant chemotherapy and surgery.
RESULTS: We show that a clonal 5F31 cell population, resistant to 1 μmol/L 5FU, express a typical cancer stem cell-like phenotype and enter into a reversible quiescent G0 state upon reexposure to higher 5FU concentrations. These quiescent cells overexpressed the tyrosine kinase c-Yes that became activated and membrane-associated upon 5FU exposure. This enhanced signaling pathway induced the dissociation of the Yes/YAP (Yes-associated protein) molecular complex and depleted nuclear YAP levels. Consistently, YES1 silencing decreased nuclear YAP accumulation and induced cellular quiescence in 5F31 cells cultured in 5FU-free medium. Importantly, YES1 and YAP transcript levels were higher in liver metastases of patients with colon cancer after 5FU-based neoadjuvant chemotherapy. Moreover, the YES1 and YAP transcript levels positively correlated with colon cancer relapse and shorter patient survival (P < 0.05 and P < 0.025, respectively).
CONCLUSIONS: We identified c-Yes and YAP as potential molecular targets to eradicate quiescent cancer cells and dormant micrometastases during 5FU chemotherapy and resistance and as predictive survival markers for colon cancer. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24323901      PMCID: PMC4387277          DOI: 10.1158/1078-0432.CCR-13-1854

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.

Authors:  A Vassilev; K J Kaneko; H Shu; Y Zhao; M L DePamphilis
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 3.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

4.  Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

Authors:  W Wang; S Marsh; J Cassidy; H L McLeod
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

5.  Nonreceptor tyrosine kinase c-Yes interacts with occludin during tight junction formation in canine kidney epithelial cells.

Authors:  Yan-Hua Chen; Qun Lu; Daniel A Goodenough; Beverly Jeansonne
Journal:  Mol Biol Cell       Date:  2002-04       Impact factor: 4.138

6.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

7.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

8.  Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate.

Authors:  Emmanuelle Leteurtre; Valérie Gouyer; Karine Rousseau; Odile Moreau; Alain Barbat; Dallas Swallow; Guillemette Huet; Thécla Lesuffleur
Journal:  Biol Cell       Date:  2004-03       Impact factor: 4.458

Review 9.  The role of CXC chemokines and their receptors in cancer.

Authors:  Jo Vandercappellen; Jo Van Damme; Sofie Struyf
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

10.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Authors:  Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

View more
  103 in total

1.  Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ.

Authors:  Victoria Llado; Yuki Nakanishi; Angeles Duran; Miguel Reina-Campos; Phillip M Shelton; Juan F Linares; Tomoko Yajima; Alex Campos; Pedro Aza-Blanc; Michael Leitges; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cell Rep       Date:  2015-02-05       Impact factor: 9.423

Review 2.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

3.  Downregulation of WW domain-containing oxidoreductase leads to tamoxifen-resistance by the inactivation of Hippo signaling.

Authors:  Juan Li; Xuefei Feng; Canyu Li; Jie Liu; Pingping Li; Ruiqi Wang; He Chen; Peijun Liu
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-02

Review 4.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Authors:  Min Hwan Kim; Joon Kim
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

5.  Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A.

Authors:  Madhuram Khandelwal; Vivek Anand; Sandeep Appunni; Amlesh Seth; Prabhjot Singh; Sandeep Mathur; Alpana Sharma
Journal:  Mol Cell Biochem       Date:  2018-01-24       Impact factor: 3.396

6.  High aldehyde dehydrogenase activity does not protect colon cancer cells against TPCS2a-sensitized photokilling.

Authors:  Judith Jing Wen Wong; Pål Kristian Selbo
Journal:  Photochem Photobiol Sci       Date:  2020-02-28       Impact factor: 3.982

Review 7.  Therapeutic targeting of gastrointestinal cancer stem cells.

Authors:  Jonathan Stem; John C Flickinger; Dante Merlino; Ellen M Caparosa; Adam E Snook; Scott A Waldman
Journal:  Regen Med       Date:  2019-04-26       Impact factor: 3.806

8.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

9.  Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells.

Authors:  Liangang Ma; Jianxin Cui; Hongqing Xi; Shibo Bian; Bo Wei; Lin Chen
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

10.  Dichotomous role of the human mitochondrial Na+/Ca2+/Li+ exchanger NCLX in colorectal cancer growth and metastasis.

Authors:  Trayambak Pathak; Maxime Gueguinou; Vonn Walter; Celine Delierneux; Martin T Johnson; Xuexin Zhang; Ping Xin; Ryan E Yoast; Scott M Emrich; Gregory S Yochum; Israel Sekler; Walter A Koltun; Donald L Gill; Nadine Hempel; Mohamed Trebak
Journal:  Elife       Date:  2020-09-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.